Altimmune (Nasdaq: ALT) will report its second quarter 2026 financial results on Wednesday, August 12, 2026. Management will host a conference call and webcast at 8:30 a.m. ET to review results and provide a business update, with live access and a replay available via the company’s Investor Relations website.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Context
Earnings-date history recorded both 6.54% and -2.19% 24-hour reactions, so precedent was mixed. The ...
Analysis
Earnings-date history recorded both 6.54% and -2.19% 24-hour reactions, so precedent was mixed. The active S-3/A shelf, marked not effective, adds capital-markets context; the August 12 report is the next disclosed catalyst.
"treatment of metabolic dysfunction-associated steatohepatitis (MASH)"
Metabolic dysfunction-associated steatohepatitis is a liver disease in which fat buildup tied to metabolic problems such as obesity and diabetes leads to inflammation and scarring, like rust forming inside a machine that gradually impairs function. It matters to investors because its growing prevalence creates large markets for drugs, diagnostics and care, and clinical trial results, approvals, or reimbursement decisions can sharply change the value of healthcare companies working in this area.
glp-1 receptorsmedical
"targeting both glucagon and GLP-1 receptors"
Cell-surface proteins that bind the hormone glucagon-like peptide-1 (GLP-1) and trigger signals regulating insulin release, appetite, and blood sugar. Think of them as locks on certain cells where GLP-1 is the key; drugs that mimic or activate these receptors can amplify the hormone’s effects. They matter to investors because drugs targeting GLP-1 receptors are central to treatments for diabetes and obesity, so trial results and approvals can materially affect company valuations and market opportunity.
alcohol use disordermedical
"MASH, alcohol use disorder (AUD) and alcohol-associated liver disease"
A chronic medical condition characterized by an inability to control or stop drinking despite negative effects on health, work, relationships or safety; it ranges from mild to severe based on frequency, loss of control, and withdrawal symptoms. Investors care because its prevalence and treatment options affect markets for pharmaceuticals, medical services and health-related productivity—think of it like a long-running equipment fault in a factory that reduces output and creates demand for repairs and preventive solutions.
alcohol-associated liver diseasemedical
"alcohol use disorder (AUD) and alcohol-associated liver disease (ALD)"
Alcohol-associated liver disease is damage to the liver caused by prolonged heavy alcohol use, ranging from fat buildup and inflammation to permanent scarring (cirrhosis) or liver failure. It matters to investors because its prevalence and severity drive demand for medical tests, hospital care, drugs and medical devices, and influence health-care costs, regulatory attention, and workforce productivity—similar to how a failing engine raises repair bills and reduces a vehicle’s usefulness.
GAITHERSBURG, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026.
Altimmune management will host a conference call at 8:30 a.m. ET on August 12 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website.
Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action investigational therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on X
Investor Contact: Luis Sanay, CFA Vice President, Investor Relations ir@altimmune.com
When will Altimmune (ALT) report its Q2 2026 financial results?
Altimmune will report its second quarter 2026 financial results on August 12, 2026. According to Altimmune, the release will be accompanied by a management conference call and webcast discussing the financial results and providing a broader business update for investors.
What time is Altimmune's Q2 2026 earnings conference call on August 12, 2026?
Altimmune's Q2 2026 earnings conference call is scheduled for 8:30 a.m. ET on August 12, 2026. According to Altimmune, management will discuss quarterly financial results and offer a business update, with investors able to access the event via a live webcast.
How can investors access the Altimmune (ALT) Q2 2026 earnings webcast and dial-in details?
Investors can access the Q2 2026 earnings webcast through Altimmune’s Investor Relations website. According to Altimmune, participants who want to join by phone must register online to receive dial-in numbers and a unique PIN before the August 12, 2026 call.
Will a replay be available for Altimmune's Q2 2026 earnings call on August 12, 2026?
Yes, a replay of Altimmune’s Q2 2026 earnings call will be available on the Investor Relations website. According to Altimmune, the replay will be accessible shortly after the call and remain available to investors for up to three months.
What is Altimmune (ALT) and what is its lead clinical candidate pemvidutide?
Altimmune is a late clinical-stage biopharmaceutical company focused on serious liver diseases. According to Altimmune, its lead candidate pemvidutide is a dual-action investigational therapy targeting glucagon and GLP-1 receptors for MASH, AUD, and alcohol-associated liver disease.
Where can investors find more information or contact Altimmune's investor relations team?
Investors can find more information on www.altimmune.com and the Investor Relations webpage. According to Altimmune, investor inquiries may be directed to Vice President of Investor Relations Luis Sanay, CFA, via the email address ir@altimmune.com provided in the announcement.
